Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H12Cl2N2O5 |
Molecular Weight | 323.129 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H](NC(=O)C(Cl)Cl)[C@@H](O)C1=CC=C(C=C1)[N+]([O-])=O
InChI
InChIKey=WIIZWVCIJKGZOK-IUCAKERBSA-N
InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m0/s1
Molecular Formula | C11H12Cl2N2O5 |
Molecular Weight | 323.129 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21742120Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/120206 | https://www.ncbi.nlm.nih.gov/pubmed/4432410 | https://www.ncbi.nlm.nih.gov/pubmed/403980
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21742120
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/120206 | https://www.ncbi.nlm.nih.gov/pubmed/4432410 | https://www.ncbi.nlm.nih.gov/pubmed/403980
Dextramycin ((S, S)-p-Chloramphenicol) is an optical isomer of Chloramphenicol, a broad-spectrum antibiotic with historical veterinary use in all major food-producing animals. The drug is biosynthesized by the soil organism Streptomyces venezuelae and several other actinomycetes and is chemically synthesized for commercial use. Chloramphenicol occurs in the meta-configuration and in the para-configuration and it contains two chiral centers thus in total eight different isomeric configurations exist. All para-stereoisomers are biologically active and 0.5% solution of Dextramycin shows antimicrobial activity. Currently, Chloramphenicol has banned for use in all food-producing animals.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0015934 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4599619 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. | 2006 |
|
Amphenicol and macrolide derived antibiotics inhibit paraoxonase enzyme activity in human serum and human hepatoma cells (HepG2) in vitro. | 2006 Jan |
|
A Role for the SmpB-SsrA system in Yersinia pseudotuberculosis pathogenesis. | 2006 Jan |
|
Expression, purification and crystallization of 2-oxo-hept-4-ene-1,7-dioate hydratase (HpcG) from Escherichia coli C. | 2006 Oct 1 |
|
A study on tinea gladiatorum in young wrestlers and dermatophyte contamination of wrestling mats from Sari, Iran. | 2007 May |
|
Isolation of Scopulariopsis spp. fungi from Psoroptes cuniculi body surface and evaluation of their entomopathogenic role. | 2008 Apr |
|
Characteristics of the Turkish isolates of Francisella tularensis. | 2008 May |
|
Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. | 2008 Sep 2 |
|
Cloning and functional characterization of carotenoid cleavage dioxygenase 4 genes. | 2009 |
|
Prevention, treatment and rehabilitation. | 2009 Dec |
|
Rab11A-controlled assembly of the inner membrane complex is required for completion of apicomplexan cytokinesis. | 2009 Jan |
|
Latherin: a surfactant protein of horse sweat and saliva. | 2009 May 29 |
|
3-Methyl-1-butanol production in Escherichia coli: random mutagenesis and two-phase fermentation. | 2010 Apr |
|
Relationships between chemical oxygen demand (COD) components and toxicity in a sequential anaerobic baffled reactor/aerobic completely stirred reactor system treating Kemicetine. | 2010 Apr 15 |
|
Comparative genomics reveals a functional thyroid-specific element in the far upstream region of the PAX8 gene. | 2010 May 14 |
|
Antimicrobial resistance of nosocomial strain of Acinetobacter baumannii in Children's Medical Center of Tehran: a 6-year prospective study. | 2010 May-Jun |
|
Three serendipitous pathways in E. coli can bypass a block in pyridoxal-5'-phosphate synthesis. | 2010 Nov 30 |
|
Synthesis and antimicrobial activity of some new thiazole, thiophene and pyrazole derivatives containing benzothiazole moiety. | 2010 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/403980
Rats were treated with Dextramycin 0.05-1.0 mg/g.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23644214
Antibacterial activity was screened against two Gram positive (Staphylococcus aureus MTCC 96, Streptococcus pyogenes MTCC 442) and two Gram negative (Escherichia coli MTCC 443, Pseudomonas aeruginosa MTCC 441) bacteria by using gentamycin, ampicillin, chloramphenicol, ciprofloxacin, norfloxacin as a standard antibacterial agents. Serial dilutions were prepared in primary and secondary screening. The control tube containing no antibiotic was immediately subcultured (before inoculation) by spreading a loopful evenly over a quarter of plate of medium suitable for the growth of the test organism and put for incubation at 37 C overnight. The tubes were then incubated overnight. The MIC of the control organismwas read to check the accuracy of the drug concentrations. The lowest concentration inhibiting growth of the organism was recorded as the MIC. All the tubes not showing visible growth (in the same manner as control tube described above) was subcultured and incubated overnight at 37 C. The amount of growth from the control tube before incubation (which represents the original inoculum) was compared. Subcultures might show: similar number of colonies indicating bacteriostatic; a reduced number of colonies indicating a partial or slow bactericidal activity and no growth if the whole inoculum has been killed. The test must include a second set of the same dilutions inoculated with an organism of known sensitivity. Each synthesized drug was diluted obtaining 2000 mg/mL concentration, as a stock solution. In primary screening 500, 250 and 125 mg/mL concentrations of the synthesized drugs were taken. The active synthesized drugs found in this primary screening were further tested in a second set of dilution against all microorganisms. The drugs found active in primary screening were similarly diluted to obtain 100, 50, 25, 12.5, 6.250, 3.125 and 1.5625 mg/mL concentrations. The highest dilution showing at least 99% inhibition is taken as MIC.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:30:21 GMT 2023
by
admin
on
Sat Dec 16 10:30:21 GMT 2023
|
Record UNII |
U0PWV2Z3IW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
92099
Created by
admin on Sat Dec 16 10:30:21 GMT 2023 , Edited by admin on Sat Dec 16 10:30:21 GMT 2023
|
PRIMARY | |||
|
205-161-2
Created by
admin on Sat Dec 16 10:30:21 GMT 2023 , Edited by admin on Sat Dec 16 10:30:21 GMT 2023
|
PRIMARY | |||
|
U0PWV2Z3IW
Created by
admin on Sat Dec 16 10:30:21 GMT 2023 , Edited by admin on Sat Dec 16 10:30:21 GMT 2023
|
PRIMARY | |||
|
DTXSID40158453
Created by
admin on Sat Dec 16 10:30:21 GMT 2023 , Edited by admin on Sat Dec 16 10:30:21 GMT 2023
|
PRIMARY | |||
|
134-90-7
Created by
admin on Sat Dec 16 10:30:21 GMT 2023 , Edited by admin on Sat Dec 16 10:30:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |